AQST Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. (AQST) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 33% planned / 67% discretionary
Largest single sale: $125.4K.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Korczynski Sherry | Chief Commercial Officer | Sell 10b5-1 | 8,750 | $5.22 | $45.7K | 235,689 −3.6% of holding | |
| Barber Daniel | President and CEO | Sell | 25,000 | $4.29 | $107.2K | 585,574 −4.1% of holding | |
| Barber Daniel | President and CEO | Sell | 20,369 | $4.00 | $81.5K | 610,574 −3.2% of holding | |
| Barber Daniel | President and CEO | Sell | 4,631 | $4.03 | $18.7K | 630,943 −0.7% of holding | |
| Krop Julie | Director | Sell 10b5-1 | 25,000 | $5.02 | $125.4K | None left | |
| Barber Daniel | President and CEO | Sell | 25,000 | $4.16 | $104.0K | 635,574 −3.8% of holding | |
| Barber Daniel | President and CEO | Sell | 8,257 | $4.29 | $35.4K | 660,574 −1.2% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.